Market Overview

The global Large Volume Parenteral (LVP) market reached a size of USD 10.4 Billion in 2024. It is forecasted to grow to USD 17.0 Billion by 2033, exhibiting a compound annual growth rate (CAGR) of 5.34% during the period from 2025 to 2033. LVPs are single-dose injections packaged in containers exceeding 100ml and used for direct administration of drugs into blood vessels and tissues via skin or external boundaries. This market growth is driven by increasing patient needs for effective nutrient delivery and surgical drug administration. 

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Large Volume Parenteral Market Key Takeaways

• The global large volume parenteral market size was USD 10.4 Billion in 2024.
• The market is expected to grow at a CAGR of 5.34% during 2025-2033.
• The forecast period for the market is from 2025 to 2033.
• LVPs are widely used for administering nutrients to patients unable to eat orally, due to malnutrition and premature births.
• They find application in treating esophageal obstruction, gastrointestinal diseases, cancer, and ulcers.
• LVPs play a critical role in heart surgeries by preventing ischemic injury during reperfusion.
• Rising incidences of non-communicable diseases globally are fueling the demand for nutrient-rich LVPs.

Sample Request Link: https://www.imarcgroup.com/Large-Volume-Parenteral-Market/requestsample

Market Growth Factors

Another factor driving the market is the increasing prevalence of malnutrition, increasing natality rate, and the increasing number of premature births worldwide. The LVPs market is expected to grow due to the high demand for parenteral nutrition for patients unable to consume food by the oral route. LVPs are also used in patients with esophageal obstruction, gastrointestinal diseases, cancer, and ulcers to deliver essential nutrients, driving market growth.

Large Volume Parenteral (LVP) solutions are commonly used in cardiac surgery for injury caused by hypoperfusion (ischemia) and its reversal (reperfusion). Additionally, there has been a demand for safer, faster and more effective methods of drug administration in the perioperative care of surgical patients. This also provides the basis for the development of minimally intrusive dosage delivery methods.

The increasing consumption of fast food worldwide has directly resulted in the increased incidence of non-communicable diseases such as hypertension, diabetes, obesity, and metabolic syndrome, and this is expected to positively impact the demand for LVPs, comprising dextrose, amino acids, lipids, electrolytes, trace metals, vitamins, and others administered by parenteral delivery. These formulations meet the special nutritional needs of affected patients, hence, ensuring a sustained demand for LVPs.

Market Segmentation

By Type:

• Soft Bag LVP: Flexible containers used to deliver single-dose parenteral solutions greater than 100ml.
• Plastic Bottle LVP: Rigid plastic containers serving as packaging for large volume sterile injections.
• Glass Bottle LVP: Traditional glass bottles employed for packaging sterilized large volume parenteral drugs.

By Volume:

• 100 ML - 250 ML: LVP products with volumes between 100 to 250 milliliters.
• 250 ML - 500 ML: Parenteral solutions packaged in volumes from 250 to 500 milliliters.
• 500 ML - 1000 ML: Medium-volume LVP products ranging from 500 to 1000 milliliters.
• 1000 ML - 2000 ML: Large volume injections packaged between 1 to 2 liters.
• 2000 ML and More: Very large volume parenteral solutions exceeding 2 liters in capacity.

By Application:

• Therapeutic Injections: LVPs used for administering therapeutic drugs intravenously or intramuscularly.
• Fluid Balance Injections: Solutions used to maintain or restore body fluid balance.
• Nutritious Injections: Nutrient-rich injectable solutions for patients with nutritional deficiencies.

By End Users:

• Hospitals: Primary users for intravenous LVP administration across various departments.
• Clinics: Smaller healthcare facilities utilizing LVPs for outpatient treatments.
• Others: Additional end users including home healthcare and specialized treatment centers.

Regional Insights

The report covers multiple regions including Asia-Pacific, Europe, North America, Latin America, and the Middle East and Africa, with key countries such as the United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, and Mexico. However, the source does not specify a dominant region or precise regional statistics.

Key Players

• Albert David Ltd.
• B. Braun Melsungen AG
• Baxter International Inc.
• BML Parenteral Drugs
• Fresenius Kabi AG
• Grifols S.A
• Otsuka Pharmaceutical Co. Ltd
• Pharmaceutical Solutions Industry Ltd.
• Sichuan Kelun Pharmaceutical Co. Ltd.
• Thermo Fisher Scientific Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=5711&flag=E\

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302